Low prevalence of PANK2 mutations in Brazilian patients with early onset generalised dystonia and basal ganglia abnormalities on MRI Neurodegeneration with brain iron accumulation (NBIA) is a heterogenous group of degenerative diseases presenting with movement disorders. Causative mutations have been identified, first in PANK2, encoding pantothenate kinase 2, and later in PLA2G6, a calcium independent phospholipase A2 enzyme. 1 2 NBIA types 1 and 2 are the denominations used to label these two entities. The clinical picture includes pyramidal syndrome, movement disorders, cerebellar dysfunction, opthalmoparesis and ocular disturbance. A neuroradiological hallmark of NBIA type 1 is the "eye-of-the-tiger" sign, characterised by bilateral areas of hyperintensity surrounded by a ring of hypointensity in the medial globus pallidus on T2-weighted MRI. Radiological findings in NBIA type 2 comprise cortical atrophy in the cerebellum, increased iron deposition in globus pallidi and substantia nigra seen as reduced signal on T2 FLAIR and T2* gradient and diffusion weighted MRI sequences, reduced volume of the optic chiasm and optic nerves and cerebral white matter changes. In this paper, we report clinical, neurological and molecular findings of Brazilian patients with clinical diagnosis of NBIA type 1.
METHODS
We identified consecutive patients during the years of 2005 and 2006 in the UFMG Movement Disorders Clinic with early onset generalised dystonia and basal ganglia abnormalities on neuroimaging studies compatible with the diagnosis of NBIA. We performed a detailed family history assessment and neurological exam and rated dystonia with the BurkeFahneMarsden Scale. DNA was extracted from peripheral lymphocytes according to routine procedures. Amplification of the coding exons of PANK2 by polymerase chain reaction was performed as previously described, followed by sequencing. 1 The study was approved by the local ethics committee and recruited patients provided signed informed consent.
RESULTS
We examined 576 patients, of whom 195 had a diagnosis of dystonia. From the dystonia group, 14% had early onset (age at onsetÀ14.8 (7.7) years) and 6 (3% of all dystonia patients) displayed imaging changes in the basal ganglia consistent with those seen in NBIA type 1: five had the typical "eye-of-the-tiger " sign and one had a reduction in T2 signal in the globus pallidi and substantia nigra ( Table 1 ). Blood count, liver and kidney function, lipid profile, alphafetoprotein, serum B12, folate, copper, ceruloplasmin, ferritin, serum immunoglobulin, creatinine phosphokinase, serum lactate and ammonia were normal in all patients submitted to this study. The age at onset of NBIA was 15.8(10.5) years. Sequence analysis revealed that three brothers had a homozygous mutation (N294I) of the PANK2 gene. These patients, born of a consanguineous marriage, had onset of their illness at the age of 16, 26 and 30 years, presenting with focal dystonia (writer's cramp), paroxysmal dystonia, epilepsy, Parkinsonism (hypophonia, bradikynesia, postural instability, festination and gait freezing), dysarthria, pyramidal signs and the "eye-of-the-tiger sign" on MRI. The illness of all patients has displayed a slow progression. The BurkeFahneMarsden Scale scores of the patients were, respectively, 7, 14 and 10 and did not change over time. There was no response to therapeutic agents such as levodopa and biperiden. Sequence analysis of the PANK2 gene of the other three patients, two with the typical "eye-ofthe-tiger " sign, did not reveal mutations in PANK2. 
CONCLUSION
In a large consecutive series of patients with dystonia, we identified 3% of patients with clinical and radiological features of NBIA. This rather high frequency of a rare illness is most likely accounted for the selection bias often seen in tertiary health units. Previous studies identified PANK2 mutations in the majority of typical and one third of atypical cases of NBIA. 3 In those series, there were no mutations of this gene in patients without the "eye-of-the-tiger" sign. In line with this finding, we identified the N294I mutation in three patients with typical "eye-of-the-tiger " sign on MRI. In contrast, we could not find any mutations in two patients with the typical sign. Several authors have found a tight correlation between the presence of "the eye-of-the-tiger" sign and PANK2 gene mutations, suggesting that this neurorradiology finding is a pathognomonic feature of NBIA type 1. 3 However, other authors have reported patients with "eye-ofthe-tiger sign" without PANK2 mutations. 4 Conversely, N294I mutation in PANK2 has already been described in patients with atypical disease, that is, late onset, pure Parkinsonism and slow progression. 3 Moreover, there are reports of patients carrying PANK2 mutation who initially presented with the "eye-of-the-tiger" sign, which disappeared later during the course of the disease. 5 Despite the small number of subjects in our study, our findings support that notion that PANK2 mutations are not invariably associated with the "eye-of-thetiger sign". 
METHODS
Thirteen subjects with clinical symptoms suggestive of IBM underwent complete clinical workup, including electrophysiology, muscle biopsy and [ 11 C]PIB-PET. Biopsy specimens underwent standard histopathological staining. Based on clinical, electrophysiological and standard histopathological criteria, seven subjects were diagnosed as having IBM, two as having polymyositis, two as having neurogenic muscle atrophy, one as having peripheral neuropathy and one as having myalgia of unclear aetiology.
Demographic and clinical details as well as biopsy results can be provided by the authors on request. The analysis was approved by the ethics committee of the University of Tuebingen. All subjects gave written informed consent.
Twenty minutes after intravenous bolus injection of 740MBq [ 
RESULTS
All non-IBM subjects presented with [
11 C] PIB-SUV levels below 0.5 (highest 0.48dthe deltoid muscles of subject non-IBM-4). All patients that were classified as 'IBM' after the clinical workup, including standard histopathological parameters, presented at least in one investigated muscle with [
11 C] PIB-SUV levels above 0.5. Six of seven IBM patients showed PIB-SUV levels of 0.6 and higher in at least one gastrocnemius muscle, and the median [ 11 C]PIB-SUV of the gastrocnemius muscles was significantly higher in IBM patients than in non-IBM subjects (Wilcoxon rank sum test, p¼0.004). In three IBM patients, [
11 C]PIB-SUV levels $0.5 were also found in additional muscles such as the vastus lateralis, deltoid and long finger flexor muscles. Details are supplied in the supplementary table (available online). Figure 1 shows PET/CT images (SUV) of the lower legs of patient non-IBM-6 (this subject had the highest gastrocnemius [ 11 C]PIB-SUV levels among the non-IBM subjects; SUV gastrocnemius ¼0.47/0.45, left/right) and an IBM subject (IBM-6, SUV gastrocnemius ¼ 0.68/0.73).
Biopsies were made in different muscles (gastrocnemius, vastus lateralis, deltoid). In two patients, muscle biopsies were available for muscles with a [ 11 C]PIB-SUV of
